GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes ...

Researchers in South Korea have developed an organoid disease model and non-destructive stiffness analysis technology for evaluating the efficacy of new drugs for fatty liver disease. The research ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Home; Articles; Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures ...

But the experimental drug did show a subsiding of metabolic dysfunction-associated steatohepatitis (MASH) without a worsening of liver scarring in up to 59.1% of participants in the 212-patient trial.

Research by Takebe et al. demonstrated that vascularised liver organoids derived from induced pluripotent stem cells (iPSCs) ...